Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival

Francis J. Giles, Hagop M. Kantarjian, B. Nebiyou Bekele, Jorge E. Cortes, Stephan Faderl, Deborah A. Thomas, Taghi Manshouri, Anna Rogers, Michael J. Keating, Moshe Talpaz, Susan O'Brien, Maher Albitar

Research output: Contribution to journalArticle

Abstract

Increased angiogenesis is important in the pathophysiology of haematological malignancies. Cyclooxygenase-2 (Cox-2) converts arachidonic acid to prostaglandins, which induce expression of angiogenic factors, including vascular endothelial growth factor (VEGF), basic-fibroblast growth factor, transforming growth factor-β and interleukin 6. Cox-2 may also reduce apoptosis and reduce cellular attachment to the extracellular matrix (ECM). Increased bone marrow (BM) vascularity, increased BM cellular and plasma VEGF levels, and decreased progenitor adherence to BM ECM have all been observed in chronic myeloid leukaemia (CML). We investigated the prognostic significance of levels of Cox-2 in BM cells from patients with CML. Western blot and solid-phase radioimmunoassay (RIA) were used to measure Cox-2 BM levels in 149 patients with chronic phase CML (CP CML). Results were compared with those of normal controls. Expression of Cox-2 was significantly higher in CML than in normal controls (P < 0.0001). Increasing levels of Cox-2 were significantly associated with shorter survival (P = 0.0002, Cox proportional hazard model). A multivariate model based on Cox-2 and degree of splenomegaly was developed for survival in patients with early CP CML. Agents that inhibit Cox-2 activity merit investigation in patients with CP CML.

Original languageEnglish (US)
Pages (from-to)38-45
Number of pages8
JournalBritish Journal of Haematology
Volume119
Issue number1
DOIs
StatePublished - Oct 29 2002
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cyclooxygenase 2
Bone Marrow
Survival
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Vascular Endothelial Growth Factor A
Extracellular Matrix
Angiogenesis Inducing Agents
Splenomegaly
Transforming Growth Factors
Fibroblast Growth Factor 2
Hematologic Neoplasms
Proportional Hazards Models
Arachidonic Acid
Bone Marrow Cells
Prostaglandins
Radioimmunoassay
Interleukin-6
Western Blotting
Apoptosis

Keywords

  • Angiogenesis
  • CML
  • Cox-2
  • Prognosis
  • VEGF

ASJC Scopus subject areas

  • Hematology

Cite this

Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. / Giles, Francis J.; Kantarjian, Hagop M.; Bekele, B. Nebiyou; Cortes, Jorge E.; Faderl, Stephan; Thomas, Deborah A.; Manshouri, Taghi; Rogers, Anna; Keating, Michael J.; Talpaz, Moshe; O'Brien, Susan; Albitar, Maher.

In: British Journal of Haematology, Vol. 119, No. 1, 29.10.2002, p. 38-45.

Research output: Contribution to journalArticle

Giles, FJ, Kantarjian, HM, Bekele, BN, Cortes, JE, Faderl, S, Thomas, DA, Manshouri, T, Rogers, A, Keating, MJ, Talpaz, M, O'Brien, S & Albitar, M 2002, 'Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival', British Journal of Haematology, vol. 119, no. 1, pp. 38-45. https://doi.org/10.1046/j.1365-2141.2002.03784.x
Giles, Francis J. ; Kantarjian, Hagop M. ; Bekele, B. Nebiyou ; Cortes, Jorge E. ; Faderl, Stephan ; Thomas, Deborah A. ; Manshouri, Taghi ; Rogers, Anna ; Keating, Michael J. ; Talpaz, Moshe ; O'Brien, Susan ; Albitar, Maher. / Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. In: British Journal of Haematology. 2002 ; Vol. 119, No. 1. pp. 38-45.
@article{b9cdfccb704f496da56b71ba511c9b46,
title = "Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival",
abstract = "Increased angiogenesis is important in the pathophysiology of haematological malignancies. Cyclooxygenase-2 (Cox-2) converts arachidonic acid to prostaglandins, which induce expression of angiogenic factors, including vascular endothelial growth factor (VEGF), basic-fibroblast growth factor, transforming growth factor-β and interleukin 6. Cox-2 may also reduce apoptosis and reduce cellular attachment to the extracellular matrix (ECM). Increased bone marrow (BM) vascularity, increased BM cellular and plasma VEGF levels, and decreased progenitor adherence to BM ECM have all been observed in chronic myeloid leukaemia (CML). We investigated the prognostic significance of levels of Cox-2 in BM cells from patients with CML. Western blot and solid-phase radioimmunoassay (RIA) were used to measure Cox-2 BM levels in 149 patients with chronic phase CML (CP CML). Results were compared with those of normal controls. Expression of Cox-2 was significantly higher in CML than in normal controls (P < 0.0001). Increasing levels of Cox-2 were significantly associated with shorter survival (P = 0.0002, Cox proportional hazard model). A multivariate model based on Cox-2 and degree of splenomegaly was developed for survival in patients with early CP CML. Agents that inhibit Cox-2 activity merit investigation in patients with CP CML.",
keywords = "Angiogenesis, CML, Cox-2, Prognosis, VEGF",
author = "Giles, {Francis J.} and Kantarjian, {Hagop M.} and Bekele, {B. Nebiyou} and Cortes, {Jorge E.} and Stephan Faderl and Thomas, {Deborah A.} and Taghi Manshouri and Anna Rogers and Keating, {Michael J.} and Moshe Talpaz and Susan O'Brien and Maher Albitar",
year = "2002",
month = "10",
day = "29",
doi = "10.1046/j.1365-2141.2002.03784.x",
language = "English (US)",
volume = "119",
pages = "38--45",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival

AU - Giles, Francis J.

AU - Kantarjian, Hagop M.

AU - Bekele, B. Nebiyou

AU - Cortes, Jorge E.

AU - Faderl, Stephan

AU - Thomas, Deborah A.

AU - Manshouri, Taghi

AU - Rogers, Anna

AU - Keating, Michael J.

AU - Talpaz, Moshe

AU - O'Brien, Susan

AU - Albitar, Maher

PY - 2002/10/29

Y1 - 2002/10/29

N2 - Increased angiogenesis is important in the pathophysiology of haematological malignancies. Cyclooxygenase-2 (Cox-2) converts arachidonic acid to prostaglandins, which induce expression of angiogenic factors, including vascular endothelial growth factor (VEGF), basic-fibroblast growth factor, transforming growth factor-β and interleukin 6. Cox-2 may also reduce apoptosis and reduce cellular attachment to the extracellular matrix (ECM). Increased bone marrow (BM) vascularity, increased BM cellular and plasma VEGF levels, and decreased progenitor adherence to BM ECM have all been observed in chronic myeloid leukaemia (CML). We investigated the prognostic significance of levels of Cox-2 in BM cells from patients with CML. Western blot and solid-phase radioimmunoassay (RIA) were used to measure Cox-2 BM levels in 149 patients with chronic phase CML (CP CML). Results were compared with those of normal controls. Expression of Cox-2 was significantly higher in CML than in normal controls (P < 0.0001). Increasing levels of Cox-2 were significantly associated with shorter survival (P = 0.0002, Cox proportional hazard model). A multivariate model based on Cox-2 and degree of splenomegaly was developed for survival in patients with early CP CML. Agents that inhibit Cox-2 activity merit investigation in patients with CP CML.

AB - Increased angiogenesis is important in the pathophysiology of haematological malignancies. Cyclooxygenase-2 (Cox-2) converts arachidonic acid to prostaglandins, which induce expression of angiogenic factors, including vascular endothelial growth factor (VEGF), basic-fibroblast growth factor, transforming growth factor-β and interleukin 6. Cox-2 may also reduce apoptosis and reduce cellular attachment to the extracellular matrix (ECM). Increased bone marrow (BM) vascularity, increased BM cellular and plasma VEGF levels, and decreased progenitor adherence to BM ECM have all been observed in chronic myeloid leukaemia (CML). We investigated the prognostic significance of levels of Cox-2 in BM cells from patients with CML. Western blot and solid-phase radioimmunoassay (RIA) were used to measure Cox-2 BM levels in 149 patients with chronic phase CML (CP CML). Results were compared with those of normal controls. Expression of Cox-2 was significantly higher in CML than in normal controls (P < 0.0001). Increasing levels of Cox-2 were significantly associated with shorter survival (P = 0.0002, Cox proportional hazard model). A multivariate model based on Cox-2 and degree of splenomegaly was developed for survival in patients with early CP CML. Agents that inhibit Cox-2 activity merit investigation in patients with CP CML.

KW - Angiogenesis

KW - CML

KW - Cox-2

KW - Prognosis

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=18644386378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18644386378&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2002.03784.x

DO - 10.1046/j.1365-2141.2002.03784.x

M3 - Article

C2 - 12358901

AN - SCOPUS:18644386378

VL - 119

SP - 38

EP - 45

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -